Targeted therapy for gastric adenocarcinoma.

@article{Almhanna2012TargetedTF,
  title={Targeted therapy for gastric adenocarcinoma.},
  author={Khaldoun Almhanna},
  journal={Advances in pharmacology},
  year={2012},
  volume={65},
  pages={437-70}
}
Gastric cancer (GC) is one of the leading causes of cancer death worldwide. Despite significant improvement in understanding disease biology and recent improvements in surgical outcome, radiation techniques, and chemotherapy, the 5-year survival rates remain divsmal. Several pathways related to cell proliferation, invasion, and metastasis have been identified and evaluated as candidates for targeted treatment but despite promising preclinical data, the majority of targeted agents failed to… CONTINUE READING

4 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Targeted therapy for gastric adenocarcinoma . Gastric cancer ( GC ) is one of the leading causes of cancer death worldwide .
Recently , adding Trastuzumab - a HER-2 monoclonal antibody - to cisplatin - based chemotherapy in patients with HER-2 overexpressing gastric and gastroesophageal junction ( GEJ ) adenocarcinoma resulted in statistically significant improvement in response rate , progression - free survival , and overall survival in phase III trial .
Targeted therapy for gastric adenocarcinoma . Gastric cancer ( GC ) is one of the leading causes of cancer death worldwide .
Targeted therapy for gastric adenocarcinoma . Gastric cancer ( GC ) is one of the leading causes of cancer death worldwide .
Targeted therapy for gastric adenocarcinoma . Gastric cancer ( GC ) is one of the leading causes of cancer death worldwide .
Recently , adding Trastuzumab - a HER-2 monoclonal antibody - to cisplatin - based chemotherapy in patients with HER-2 overexpressing gastric and gastroesophageal junction ( GEJ ) adenocarcinoma resulted in statistically significant improvement in response rate , progression - free survival , and overall survival in phase III trial .
Recently , adding Trastuzumab - a HER-2 monoclonal antibody - to cisplatin - based chemotherapy in patients with HER-2 overexpressing gastric and gastroesophageal junction ( GEJ ) adenocarcinoma resulted in statistically significant improvement in response rate , progression - free survival , and overall survival in phase III trial .
All Topics